Remote & Hybrid Executive Pay in Pharma

The pharma and life sciences industry entered the remote work era with a structural disadvantage that most other sectors didn’t have: a large share of its senior workforce was already location-dependent by the nature of the science. You cannot run a GMP manufacturing line from a home office. You cannot conduct patient visits for a Phase III clinical trial over Zoom. And yet, when the 2020–2021 remote work experiment forced every industry to adapt, pharma companies made the same promises as their technology counterparts — that compensation would not be affected by where you work. Our 2022 placement data across 83 senior life sciences placements told a more nuanced story: remote roles in pharma and biotech paid an average of 7% less in total compensation than equivalent hybrid or on-site positions at the same companies.

This piece examines the specific compensation dynamics of remote versus hybrid work arrangements in the life sciences sector, where the gap between what companies promised and what the data showed was shaped by factors unique to drug development, commercialization, and regulatory work. The analysis draws on our 2022 placement data and subsequent follow-up conversations with life sciences executives across therapeutic areas and functions.

What our placement data shows

Across our 2022 life sciences senior placement dataset, the compensation gap between remote-first and hybrid/on-site roles was driven primarily by the variable and equity components, not base salary. Base salaries for remote pharma executives were within 1–2% of on-site equivalents. The gap emerged in annual bonus targets (2–4% lower for remote roles) and long-term incentive grants (6–10% lower). At the VP level in pharma, where total compensation typically ranges from $380,000 to $620,000 depending on function and company stage, a 7% gap translates to $27,000 to $43,000 in annual compensation — a material difference compounded over a multi-year tenure.

The structural explanation mirrors what we observed across industries, with a pharma-specific twist: companies offering fully remote life sciences roles were disproportionately smaller biotechs with constrained equity budgets, while the large pharma companies with robust LTI programs were also the ones most likely to require hybrid or on-site presence at their New Jersey, Boston, or San Francisco headquarters.

Field-based and MSL premiums

The most distinctive compensation dynamic in life sciences remote work is the field-based premium. Medical Science Liaisons, regional commercial directors, and field medical affairs leaders occupy a category that doesn’t exist in most other industries: they work remotely (from home offices in their territories) but are not “remote” in the sense that a regulatory affairs director working from home is remote. They travel 60–80% of the time, maintain relationships with key opinion leaders at academic medical centers, and serve as the scientific face of the company in their regions.

In our 2022 data, field-based MSL directors earned a 12–18% premium over equivalent non-field medical affairs roles. A Senior Director of MSLs overseeing an oncology field team earned a median total compensation of $485,000, compared to $410,000 for a Senior Director of Medical Affairs in a headquarters-based role at the same company. The premium reflects the difficulty of recruiting experienced MSL leaders with deep therapeutic-area expertise, established KOL networks, and willingness to maintain heavy travel schedules — a combination that narrows the candidate pool considerably.

Commercial field leadership shows a similar pattern. Regional VP-level commercial leaders in specialty pharma — responsible for sales teams covering oncology, rare disease, or immunology products — earned $420,000 to $580,000 in total compensation in our 2022 dataset, with the premium reflecting both territory revenue responsibility and the operational complexity of managing distributed sales organizations.

Which LS roles can be fully remote

Not all life sciences functions are equally suited to remote work, and the market has priced this reality into compensation structures with surprising precision. Three categories of roles have settled into genuinely remote-compatible arrangements with minimal or no compensation penalty:

Regulatory affairs. The nature of regulatory work — document preparation, agency correspondence, submission management — is inherently compatible with remote execution. Senior regulatory professionals at the VP and SVP level were among the first in pharma to negotiate permanent remote arrangements, and our data shows essentially zero compensation gap for remote regulatory roles at companies that have formally adopted remote policies. A VP of Regulatory Affairs working remotely from North Carolina for a Boston-based biotech earned the same $390,000–$450,000 range as their Boston-based counterpart.

Medical writing and publications. Medical writers and publications directors have always worked in relative isolation from the broader organization, and the transition to permanent remote work was seamless for most. Senior Director-level medical writing roles paid $280,000 to $340,000 regardless of location in our 2022 data.

Pharmacovigilance and drug safety. Post-marketing surveillance and safety reporting functions adapted quickly to remote work, particularly at companies using cloud-based safety databases. VP-level pharmacovigilance leaders earned $360,000 to $440,000 with no measurable remote penalty.

Roles that require on-site presence

The pharma functions where remote work remains impractical or impossible define the other end of the spectrum, and these roles have seen compensation premiums specifically tied to on-site requirements:

Manufacturing and quality operations. GMP manufacturing leaders, VP-level quality assurance executives, and site heads must be physically present. A VP of Manufacturing at a biologics production facility earned $420,000 to $520,000 in our 2022 data — roughly 15% above what a comparable-level headquarters role would pay, reflecting both the on-site requirement and the specialized nature of biologics manufacturing expertise.

Laboratory-based R&D. Discovery research, translational science, and CMC (chemistry, manufacturing, and controls) functions require laboratory access. Senior directors and VPs leading bench research earned premiums of 8–12% over comparable non-lab roles, and geographic concentration in Boston/Cambridge, San Francisco, and San Diego further compressed the available talent pool.

Clinical operations. While clinical development strategy can be done remotely, clinical operations leadership — managing CRO relationships, site monitoring oversight, and trial conduct — increasingly requires hybrid presence, particularly at companies running late-stage trials. VP Clinical Operations roles paid $380,000 to $480,000 with most companies requiring 2–3 days per week on-site.

Negotiating remote comp in pharma

For life sciences executives evaluating remote roles, three negotiating principles specific to the pharma context: First, understand whether the company’s remote policy applies uniformly or by function. Many pharma companies have adopted a “role-based flexibility” framework where regulatory and medical writing roles are fully remote, clinical operations is hybrid, and manufacturing is on-site. The compensation structure follows the flexibility tier, not a blanket policy. Second, negotiate the long-term incentive component separately from base salary. The LTI gap is where the remote discount lives in pharma; base salary is rarely the issue. Pushing for a larger initial equity or stock option grant can close or eliminate the gap. Third, if the role involves any field component — even partial territory responsibility or KOL engagement — negotiate for the field premium rather than accepting the headquarters comp band. The distinction between “home office with travel” and “field-based” can be worth $40,000 to $80,000 in annual compensation.

Outlook for 2023 and beyond

The remote compensation dynamics we documented in 2022 have continued to evolve. Large pharma companies have largely settled on hybrid models for headquarters-based functions, with 2–3 days per week in office becoming the industry standard. The explicit remote discount has compressed from 7% to roughly 2–4% by late 2023, as competition for specialized talent — particularly in cell and gene therapy, ADC development, and GLP-1 commercial leadership — has forced companies to compete on total compensation regardless of location. The MSL and field premium has remained stable, reflecting the persistent difficulty of recruiting experienced field medical and commercial leaders willing to maintain heavy travel schedules. For current life sciences compensation benchmarks across functions and geographies, see our 2026 Compensation Report.

The most important development for life sciences executives to track is the growing divergence between companies that have genuinely built remote-capable organizations — with robust virtual collaboration infrastructure, remote-friendly promotion practices, and distributed decision-making — and companies that have adopted remote policies on paper but continue to favor on-site employees for advancement. The latter group will eventually reconverge on hybrid mandates; the former represents genuinely durable remote opportunities. Distinguishing between the two requires reference conversations with current remote employees at the target company, not just reading the HR policy.